Controlled clinical trial with the combination therapy with metformin, thiazolidinediones, glucagon-like peptide 1 analog in patients with type 2 diabetes and metabolic syndrome
10.3760/cma.j.issn.1000-6699.2019.09.002
- VernacularTitle: 以二甲双胍、噻唑烷二酮类和胰升糖素样肽1类似物组成的三联降糖方案治疗2型糖尿病合并代谢综合征的临床对照研究
- Author:
Zhuang KANG
1
;
Zhidan LUO
2
;
Hong ZHANG
1
;
Ruijin GUO
1
;
Heng SU
1
;
Yuanming XUE
1
;
Lijing MA
1
;
Qiongli NENG
1
Author Information
1. Department of Endocrinology, the First People′s Hospital of Yunnan Province, Kunming 650011, China
2. Department of Geriatric, Chongqing People′s Hospital, Chongqing 400014, China
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus, type 2;
Metabolic syndrome;
Triple glucose-lowering therapy
- From:
Chinese Journal of Endocrinology and Metabolism
2019;35(9):736-742
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The aim of this study was to compare the efficacy and safety of metformin/thiazolidinediones (TZDs) / glucagon-like peptide 1 (GLP-1) analogs (triple therapy) with conventional glucose-lowering therapy(conventional therapy) for patients with type 2 diabetes and metabolic syndrome.
Methods:A prospective randomized-controlled 26-week study was carried out. A total of 82 patients with type 2 diabetes and metabolic syndrome were randomized to receive either triple therapy protocal or just conventional therapy, altogether with 41 cases in each group.
Results:HbA1C value was significantly reduced in triple therapy group versus the conventional therapy group [(2.23±1.75)% vs (1.48±1.59)%, P<0.05]. Values of body mass index, waist circumference, and visceral fat area were significantly reduced in triple therapy group as compared to those of conventional therapy group [(2.50±1.81 vs 0.92±1.82)kg/m2, (6.75±4.92 vs 1.66±3.25)cm, (24.10±19.10 vs 10.02±20.10)cm2, all P<0.01, respectively]. Control rates of HbA1C and fasting plasma glucose for triple therapy were higher than those for conventional therapy (both P<0.05). No hypoglycemia occurred in triple therapy group. Subjects receiving triple therapy experienced more frequent gastrointestinal side effects than those in conventional therapy group (18.87% vs 3.92%, P<0.05). The most common side event was mild nausea (90%).
Conclusion:Combination therapy with metformin/TZDs/GLP-1 analogs had statistically significant advantages in the control of body weight, waist circumference, and visceral fat area in addition to the control of blood glucose over conventional glucose-lowering therapy in our patient cohort, it seems to be an optimized therapeutic regimen for patients with type 2 diabete and metabolic syndrome.
